DRREDDY
CLSA ON DR REDDY'S : 15.07.2021
* Dr Reddy's annual report provides a roadmap to scale up key market operations, including stronger US FDA compliance, CLSA says, maintains BUY
* Annual Rpt Gives Roadmap To Scale Up Key Mkt Ops, Incl Stronger US FDA Compliance
* Continued Margin Improvement Should Drive Mid-teens YoY Earnings Growth
* MAINTAIN BUY TARGET: 6,210
MORGAN STANLEY ON DR REDDY'S : 23.06.2021
* Maintain Overweight, Target at Rs 5,859/share
* gVascepa launch a good earnings catalyst
* Expect an earnings up-cycle for DRL, driven by India/EM markets
• Niche US launches & continuing productivity gains expected
* gVascepa is an important US launch playing into this thesis
* gKuvan 500mg powder, gRevlimid, and Sputnik V are other upcoming catalysts
MS ON DR REDDY'S : 23.06.2021
* MS has an Overweight call on Dr Reddy's with an expectation of earnings upcycle, led by India/EM markets
* MAINTAIN OVERWEIGHT TARGET: 5,859
* Expect An Earnings Upcycle, Driven By India/EM Markets
* Niche US Launches & Productivity Gains Will Support Growth
* Vascepa Generic Is An Important US Launch
• Kuvan, Revlimid Generics & Sputnik V Are Other Catalysts
